-The Telegraph New Delhi: A government agency has blocked its own pledge to impose price control on more medicines by withdrawing guidelines that it had used in July this year to cap prices of drugs used to treat diabetes and cardiovascular diseases. The National Pharmaceutical Pricing Authority (NPPA) has withdrawn the guidelines issued under Paragraph 19 of the Drug Price Control Order that it had used in July this year to cap...

-The Business Standard A ray of hope for Indian generic drug makers Gilead Sciences, the California-headquartered biotechnology company, has authorised seven India-based drug makers - Cipla, Ranbaxy, Mylan, Strides Arcolab, Hetero, Cadila Healthcare and Sequent Scientific - to manufacture and sell the generic versions of its hepatitis C medicine, Sovaldi, in 91 developing countries. Earlier in the week, Lupin, the fourth largest Indian drug maker, announced that it will develop and supply...

-The Times of India MUMBAI: Treatment for HIV patients across India has taken a hit, especially in Delhi and Mumbai, due to severe stock-outs of life-saving medicines reported at government-owned centres. Shortage of first-line (initial), second-line (advanced) and paediatric HIV Drugs, besides crucial diagnostic kits, has prompted patient groups to send a legal notice to the government, pointing to the scarcity, gaps in procurement and supply of these drugs. The treatment and control...

-The Times of India MUMBAI: In a move that has surprised and shaken the industry, prices of widely-used expensive anti-diabetic and cardiac medicines will reduce by as much as 35% over the next few weeks, with the drug pricing regulator, National Pharmaceutical Pricing Authority (NPPA), deciding to bring them under price control. In a rare invocation of a lesser-used provision in the Drug Price Control Order (DPCO), NPPA has fixed the prices...

-The Business Standard   Regulator studying pricing models in various nations; draft legislation likely by end of March Pharmaceutical companies might be up for stricter price regulations. The government is planning to bring in a legislation that would take into consideration pricing models across the US, European Union (EU), China and 14 Organisation for Economic Co-operation and Development (OECD) countries. The National Pharmaceutical Pricing Authority (NPPA), which regulates prices of medicines in the market,...